You are here: Industry Insights > servier

News List

Servier Acquires Cancer Biotech Symphogen contractpharma
April 08, 2020
Strengthens R&D pipeline by acquiring antibody pipeline and next-gen antibody technologies.
Servier agrees to acquire Symphogen pharmaceutical-technology
April 07, 2020
French pharmaceutical company Servier has signed a definitive agreement to acquire 100% shares in Danish therapeutic antibody discovery firm Symphogen.
OSE Immunotherapeutics updates licensing deal with Servier pharmaceutical-technology
March 19, 2020
OSE Immunotherapeutics has amended its global licensing option agreement with Servier for sole worldwide rights to OSE-127 in autoimmune diseases.
Amgen, Cytokinetics, Servier Announce Continuation of GALACTIC-HF americanpharmaceuticalreview
March 05, 2020
Amgen, Cytokinetics, and Servier announced the Data Monitoring Committee (DMC) for GALACTIC-HF recently completed the second and final planned interim analysis ...
Servier faces courtroom in long-running Mediator death investigation fiercepharma
September 26, 2019
According to the outlet, 5 million French patients used the drug over a 30-year period, including 3 million patients who used it for stretches longer than three months.
Pall Corporation Chosen as Single-Source Supplier by Servier americanpharmaceuticalreview
July 23, 2019
Pall Corporation has been chosen by Servier, an independent international pharmaceutical company, as an exclusive technology and services provider for their Gidy, France biomanufacturing facility.
Pall, Servier Enter Biomanufacturing Tie-up contractpharma
July 22, 2019
Pall chosen as single-source supplier for Servier’s purpose built end-to-end biomanufacturing facility in Gidy, France.
Servier Breaks Ground on Paris-Saclay Research Institute americanpharmaceuticalreview
June 21, 2019
Servier has laid the foundation stone of its future Research Institute in the Paris-Saclay cluster. The new Servier Paris-Saclay Research Institute will house all of the Group's research activities located in France by 2022.
Servier Selects Yposkesi for CAR-T GMP-Mfg. contractpharma
June 10, 2019
Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T cell technology development.
Exclusive: Servier Establishes First U.S. Toehold in Boston with Immediate Focus on Oncology biospace
May 13, 2019
Less than one year after France-based Servier announced the launch of its U.S. subsidiaryServier Pharmaceuticals, the new company celebrated the grand opening of its 100-employee Boston facility that will initially focus its efforts on developing oncology

Previous page 1 2 3 Next page